Wikisage, the free encyclopedia of the second generation, is digital heritage
Brivaracetam: Difference between revisions
Jump to navigation
Jump to search
m (wData) |
m (AED categ) |
||
Line 3: | Line 3: | ||
4n propyl analog of [[levetiracetam]], this a levetiracetam may have potential in the mangement of progressive myoclonic [[epilepsy|epilepsies]] | 4n propyl analog of [[levetiracetam]], this a levetiracetam may have potential in the mangement of progressive myoclonic [[epilepsy|epilepsies]] | ||
<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670022/pdf/ndt-11-2967.pdf</ref> | <ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670022/pdf/ndt-11-2967.pdf</ref> | ||
==Links== | |||
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm | |||
{{Wikidata|Q408099}} | |||
<references/> | <references/> |
Revision as of 01:19, 30 March 2016
-
(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide
4n propyl analog of levetiracetam, this a levetiracetam may have potential in the mangement of progressive myoclonic epilepsies [1]
Links
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm